Immediate post-infusion recovery is typically 1–2 weeks; patients usually resume light activity within days. Full immune re-equilibration (as measured by T-cell and antibody profiles) takes 8–12 weeks. Clinical plateau is often reached by month 6. Disease flares can recur at any point, particularly if steroids or immunosuppressants are withdrawn too rapidly; close rheumatology monitoring is essential throughout.
Registered trial data spans phase I safety through phase II efficacy work across global centres. Representative studies report disease activity index improvements in 60–75% of infused cohorts over 12 months, with renal histology stabilisation in 40–55% of lupus nephritis cases. Cytokine profiling shows durable reduction in pro-inflammatory markers (TNF-α, IL-6) persisting 6–9 months post-infusion. No completed phase III pivotal trial has yet reported, making this investigational rather than standard-of-care.
Am I a candidate? → · Lupus (SLE): full overview → · Lupus (SLE) cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment